ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MXCT Maxcyte Inc

342.50
-2.50 (-0.72%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -0.72% 342.50 335.00 350.00 345.00 342.50 345.00 24,274 16:17:54
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 44.26M -23.57M -0.2277 -18.40 433.68M

MaxCyte, Inc. Notice of Full Year Results (5163V)

15/04/2021 7:00am

UK Regulatory


Maxcyte (LSE:MXCT)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Maxcyte Charts.

TIDMMXCT TIDMTTM

RNS Number : 5163V

MaxCyte, Inc.

15 April 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Full Year Results

Gaithersburg, Maryland - 15 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, will be announcing its financial results for the year ended 31 December 2020 on Tuesday, 20 April 2021.

Doug Doerfler, Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will host a conference call for analysts at 14.00pm BST the day of the announcement. The presentation will be available on the Investors section of MaxCyte's website on the day of the meeting at

https://investors.maxcyte.com/news-events/documents-presentations   . 

###

For further information please contact:

 
 MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Amanda Murphy, Chief Financial Officer    +1 301 944 1660 
 
   Nominated Adviser and Joint Corporate 
   Broker 
   Panmure Gordon 
   Emma Earl 
   Freddy Crossley 
   Corporate Broking 
   Rupert Dearden                             +44 (0)20 7886 2500 
 
   Joint Corporate Broker 
   Numis Securities Limited 
   James Black 
   Duncan Monteith                            +44 (0)20 7260 1000 
 Joint Corporate Broker 
  Stifel Nicolaus Europe Limited 
  Healthcare Investment Banking 
  Nicholas Moore / Ben Maddison / 
  Samira Essebiyea 
  Corporate Broking 
  Nick Adams                                +44 (0) 20 7710 7600 
 
   Financial PR Adviser                       +44 (0)203 709 5700 
   Consilium Strategic Communications         maxcyte@consilium-comms.com 
   Mary-Jane Elliott / Chris Welsh 
 

About MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies that are driving the next--generation of cell-based therapies and making a meaningful difference for patients. The Company's technology is employed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte has granted 12 strategic platform licences to leading cell-based therapy developers. Through 2020, MaxCyte has granted licenses for more than 140 cell therapy programs, with over 100 licensed for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, U.S. For more information, visit www.maxcyte.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORUSORRANUSAUR

(END) Dow Jones Newswires

April 15, 2021 02:00 ET (06:00 GMT)

1 Year Maxcyte Chart

1 Year Maxcyte Chart

1 Month Maxcyte Chart

1 Month Maxcyte Chart

Your Recent History

Delayed Upgrade Clock